Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Conditions
Interventions
Epacadostat
Pembrolizumab
+13 more
Locations
16
United States
Mayo Clinic Arizona
Phoenix, Arizona, United States
University of California San Diego Medical Center, Moores Cancer Center
La Jolla, California, United States
The Angeles Clinic and Research Institute
Los Angeles, California, United States
Mayo Clinic
Jacksonville, Florida, United States
University of Chicago
Chicago, Illinois, United States
Mayo Clinic
Rochester, Minnesota, United States
Start Date
May 2, 2017
Primary Completion Date
January 25, 2019
Completion Date
July 13, 2020
Last Updated
September 23, 2022
NCT05720117
NCT06898450
NCT06658951
NCT05098132
NCT05101070
NCT05719558
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions